Simulect 20 mg
As listed in the register: Simulect 20 mg, poeder en oplosmiddel voor oplossing voor intraveneuze infusie
20 mg · poeder en oplosmiddel voor oplossing voor infusie, poeder voor oplossing voor injectie of infusie
- Prescription only
- Cancer treatments and immune-system medicines
- Active substance
- Basiliximab
- Made by
- Novartis Europharm Limited
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
Mediclarum has not yet retrieved and stored the official label for this product, so none of its text is shown here. Open the official leaflet
How it works
From the US prescribing label for the same active substance (Simulect). It describes the substance, not this exact product.
General Mechanism of Action: Basiliximab functions as an IL-2 receptor antagonist by binding with high affinity (K a = 1 x 10 10 M -1 ) to the alpha chain of the high affinity IL-2 receptor complex and inhibiting IL-2 binding.
Basiliximab is specifically targeted against IL-2Rα, which is selectively expressed on the surface of activated T-lymphocytes.
Quoted from the prescribing label, sections “Mechanism of Action” and “Pharmacokinetics”. DailyMed · 2025-12-12
Safety of the active substance
From the US prescribing label for the same active substance (Simulect). It describes the substance, not this exact product.
WARNING Only physicians experienced in immunosuppression therapy and management of organ transplantation patients should prescribe Simulect ® (basiliximab).
- Simulect ® (basiliximab) is contraindicated in patients with known hypersensitivity to basiliximab or any other component of the formulation.
- See composition of Simulect under DESCRIPTION.
- General Simulect ® (basiliximab) should be administered under qualified medical supervision.
- Patients should be informed of the potential benefits of therapy and the risks associated with administration of immunosuppressive therapy.
The most frequently reported adverse events were gastrointestinal disorders, reported in 69% of Simulect-treated patients and 67% of placebo-treated patients.
Quoted from the US prescribing label for the same active substance. Your own pack’s leaflet is the authority for your product. DailyMed
Same active substance, strength and form in other countries
Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.
Medicine passport: one printable page to show a pharmacist abroad
United StatesNo exact match for this strength and form
European UnionNo exact match for this strength and form
SpainNo exact match for this strength and form
France1 matching products
CanadaNo exact match for this strength and form
SwitzerlandNo exact match for this strength and form
Details
| Made by | Novartis Europharm Limited |
|---|---|
| Active substance | Basiliximab |
| Used in | Cancer treatments and immune-system medicines |
| Strength | 20 mg |
| Form | poeder en oplosmiddel voor oplossing voor infusie, poeder voor oplossing voor injectie of infusie |
| Classification | L04AC02 · Cancer treatments and immune-system medicines |
| Route | intraveneus gebruik |
| Dispensing (as stated by the register) | Uitsluitend recept |
| Name in the register | Simulect 20 mg, poeder en oplosmiddel voor oplossing voor intraveneuze infusie |
| RVG | EU/1/98/084 |
Source: Geneesmiddeleninformatiebank · 2026-09-30 · not reviewed by a clinician
Bron: College ter Beoordeling van Geneesmiddelen (CBG). De Rijksoverheid is het niet automatisch eens met de inhoud van deze site. Reuse terms: CC0 1.0 (CBG website).
Same active substance
These contain the same substance. That does not mean one can replace another — ask a pharmacist.